Regenxbio

RGNX on Nasdaq. REGENXBIO licenses gene therapy technology to drugmakers and develops treatments for patients. Market value $505m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.

Capital spending looks too small to be complete, so we leave free cash flow out.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Look carefully before going further

Read the warning sign in its own filings

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
annual report to December 2025
n/a

We could not compute this from the filings.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 34 of 100. Price score: 16 of 100. Our list needs 70 on quality and 60 on price.

$7.16 a share, 31% above its 1-year low

Over the past year the price has ranged from $5.45 to $16.19.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

0.1
-0.2
-0.2
n/a
n/a
20212022202320242025
Revenue
$470m$113m$90m$83m$170m
Operating margin
34.0%-233.2%-297.1%-280.0%-94.6%
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.04bn0.04bn0.05bn0.05bn0.07bn

Health checks

  • Free cash flow positive1 of 3 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)2 of 7 checks we could run
  • Profit backed by cash (accruals)No
  • DebtUnknown
  • Revenue growth, five yearsSlow, 2.0% a year
  • Buying back its own sharesNo, 53% more shares since 2021

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $9 million last quarter, down 69% on a year ago.
  • A loss of $41 million, compared with a loss of $62 million a year ago.
  • It loses 96 cents on each $1 of sales, compared with 96 cents a year earlier.
  • 26% more shares than a year ago. Each share owns a bit less of the company.
  • Sales grew on a year ago in 2 of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$21m
March 2025$89m
June 2025$21m
September 2025$30m
December 2025$30m
March 2026$6m
June 2026$108m
September 2026$9m
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024-$51m
March 2025$6m
June 2025-$71m
September 2025-$62m
December 2025-$67m
March 2026-$90m
June 2026$23m
September 2026-$41m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
5 March 2026
Next quarterly (estimated, 10-Q)
4 February 2027

Who owns it

None of the long-term investors we follow own it. 165 funds in all.

Jun '25
Dec '25
Jun '26

Sold out this quarter

Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

3 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $949,381 of shares on the open market. 1 sold $939,970, $251,215 of it under preset trading plans.

  • Ciongoli Gregory Austin
    Director
    Bought
    Date
    27 August 2026
    Shares
    53,407
    Price
    $9.36
    Value
    $499,676
  • Ciongoli Gregory Austin
    Director
    Bought
    Date
    26 August 2026
    Shares
    49,196
    Price
    $9.14
    Value
    $449,706
  • PAKOLA STEVE
    Chief Medical Officer
    Sold
    under a preset trading plan
    Date
    2 July 2026
    Shares
    2,161
    Price
    $13.64
    Value
    $29,476
  • PAKOLA STEVE
    Chief Medical Officer
    Sold
    Date
    1 July 2026
    Shares
    36,725
    Price
    $12.86
    Value
    $472,284
  • PAKOLA STEVE
    Chief Medical Officer
    Sold
    Date
    29 June 2026
    Shares
    19,608
    Price
    $11.04
    Value
    $216,472
  • PAKOLA STEVE
    Chief Medical Officer
    Sold
    under a preset trading plan
    Date
    11 May 2026
    Shares
    15,309
    Price
    $11.02
    Value
    $168,705
  • PAKOLA STEVE
    Chief Medical Officer
    Sold
    under a preset trading plan
    Date
    10 March 2026
    Shares
    5,124
    Price
    $10.35
    Value
    $53,033

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Regenxbio’s filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 5 Mar 2026, plus the 10-Q filed 5 Nov 2026 and 11 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “These conditions raise substantial doubt about the Company's ability to continue as a going concern within 12 months from the date these consolidated financial statements were issued.”
    Show the full paragraph
    As of September 30, 2026, the Company had cash, cash equivalents and marketable securities of $ 251.0 million. In October 2026, the Company received a payment of $ 39.0 million pursuant to a settlement agreement with Sarepta Therapeutics, Inc. (Sarepta). Please refer to Note 8 for further information regarding the settlement agreement with Sarepta. Management believes the Company's cash, cash equivalents and marketable securities as of September 30, 2026, along with the settlement proceeds received in October 2026, are sufficient to fund operations into the late fourth quarter of 2027. This estimate is based on the Company's current operating plan and excludes the potential effects of any future financings or material milestone payments that may be received under the Company's licensing and collaboration arrangements. The Company has based this estimate on assumptions that may prove to be wrong, and it could exhaust its capital resources sooner than expected. These conditions raise substantial doubt about the Company's ability to continue as a going concern within 12 months from the date these consolidated financial statements were issued. The Company’s ability to continue as a going concern will depend heavily on the successful development, approval and commercialization of its product candidates and its ability to raise additional capital to fund its operations. If the Company is unable to raise capital sufficient to meet its working capital needs in the future, it may be forced to delay expenditures, reduce the scope of its development activities or make other changes to its operating plans.

    From the 10-Q filed 5 November 2026, Part I, Item 1. Financial Statements. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

  • Sales have barely grown: 2.0% a year.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.